Diana Luca

1.6k total citations
26 papers, 639 citations indexed

About

Diana Luca is a scholar working on Surgery, Epidemiology and Genetics. According to data from OpenAlex, Diana Luca has authored 26 papers receiving a total of 639 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Surgery, 10 papers in Epidemiology and 8 papers in Genetics. Recurrent topics in Diana Luca's work include Inflammatory Bowel Disease (8 papers), Microscopic Colitis (7 papers) and Lipoproteins and Cardiovascular Health (4 papers). Diana Luca is often cited by papers focused on Inflammatory Bowel Disease (8 papers), Microscopic Colitis (7 papers) and Lipoproteins and Cardiovascular Health (4 papers). Diana Luca collaborates with scholars based in United States, United Kingdom and Italy. Diana Luca's co-authors include Francesco Giuseppe De Rosa, O Leri, D. Caccavo, Antonio Amoroso, L Bonomo, Giovanni Maria Ferri, Antonella Afeltra, Mary Keir, Sharon O’Byrne and Suzanne M. Jan de Beur and has published in prestigious journals such as Circulation, Gastroenterology and Gut.

In The Last Decade

Diana Luca

25 papers receiving 616 citations

Peers

Diana Luca

GENET

EPIDE

IMMUN

SURGE

NEPHR

Mitsuo Okada Japan

Aysel Ülker Türkiye

T. Fukuda Japan

Tadahiko Fuchigami Japan

Tamás Dinya Hungary

Hülya Çetınkaya Türkiye

Keith Leiper United Kingdom

Jade E. Hollis‐Moffatt New Zealand

A Lobo-Yeo United Kingdom

Sinikka Koskinen Finland

Mitsuo Okada Japan

Diana Luca

218 ×0.7

GENET

245 ×1.1

EPIDE

77 ×0.5

IMMUN

539 ×4.0

SURGE

125 ×0.9

NEPHR

Citations per year, relative to Diana Luca Diana Luca (= 1×) peers Mitsuo Okada

Countries citing papers authored by Diana Luca

Since Specialization

Citations

This map shows the geographic impact of Diana Luca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana Luca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana Luca more than expected).

Fields of papers citing papers by Diana Luca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana Luca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana Luca. The network helps show where Diana Luca may publish in the future.

Co-authorship network of co-authors of Diana Luca

This figure shows the co-authorship network connecting the top 25 collaborators of Diana Luca. A scholar is included among the top collaborators of Diana Luca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana Luca. Diana Luca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Luca, Diana, Adrián Estrada Corona, K. J. Walsh, et al.. (2025). Using Sagittal Length to Differentiate Between PRI-MUS 4 and PRI-MUS 5 Lesions. JU Open Plus. 3(10).

Luca, Diana, K. J. Walsh, Zhongyue Zhang, et al.. (2025). Combining Prostate MRI and Microultrasound to Omit Systematic Biopsy. JU Open Plus. 3(2). 1 indexed citations

Beur, Suzanne M. Jan de, Annabel Nixon, Christina Theodore‐Oklota, et al.. (2023). Burosumab Improves Patient-Reported Outcomes in Adults With Tumor-Induced Osteomalacia: Mixed-Methods Analysis. Journal of Bone and Mineral Research. 38(11). 1654–1664. 10 indexed citations

Sugarman, Jeremy, Dale J. Hamilton, Laila Tabatabai, et al.. (2022). The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome. Bone. 166. 116598–116598. 10 indexed citations

Beur, Suzanne M. Jan de, Paul D. Miller, Thomas J. Weber, et al.. (2020). Burosumab for the Treatment of Tumor-Induced Osteomalacia. Journal of Bone and Mineral Research. 36(4). 627–635. 109 indexed citations

Carpenter, Thomas O., Paul D. Miller, Thomas J. Weber, et al.. (2020). OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome. Journal of the Endocrine Society. 4(Supplement_1). 1 indexed citations

Beur, Suzanne M. Jan de, Paul D. Miller, Thomas J. Weber, et al.. (2019). OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome. Journal of the Endocrine Society. 3(Supplement_1). 10 indexed citations

Voidăzan, Septimiu, et al.. (2018). Bacteriuria and asymptomatic infection in chronic patients with indwelling urinary catheter. Medicine. 97(33). e11796–e11796. 20 indexed citations

Baruch, Amos, Diana Luca, Robert S. Kahn, et al.. (2017). A phase 1 study to evaluate the safety and LDL cholesterol–lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9. Clinical Cardiology. 40(7). 503–511. 15 indexed citations

10.

Keir, Mary, Gaik W. Tew, Diana Luca, et al.. (2014). Su1276 αE Integrin Expression As a Predictive Biomarker for Induction of Clinical Remission by Etrolizumab: Analysis of a Phase II Trial in Moderate-to-Severely Active Ulcerative Colitis. Gastroenterology. 146(5). S–422. 2 indexed citations

11.

Keir, Mary, Gaik W. Tew, Diana Luca, et al.. (2014). OP010 AlphaE integrin expression as a predictive biomarker for induction of clinical remission by etrolizumab: Analysis of a phase II trial in moderate-to-severely active ulcerative colitis. Journal of Crohn s and Colitis. 8. S7–S7. 3 indexed citations

12.

Baruch, Amos, Maya K. Leabman, Nageshwar Budha, et al.. (2013). Abstract 12009: Effect of RG7652, a mAb Against PCSK9, on Apolipoprotein B, Oxidized LDL, Lipoprotein(a) and Lipoprotein-Associated Phospholipase A2 in Healthy Individuals With Elevated LDL-c. Circulation. 128. 2 indexed citations

13.

Faubion, William A., Joel G. Fletcher, Sharon O’Byrne, et al.. (2013). EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging. The American Journal of Gastroenterology. 108(12). 1891–1900. 82 indexed citations

14.

Vermeire, Séverine, Sharon O’Byrne, Marna Williams, et al.. (2013). 159 Differentiation Between Etrolizumab (Rhumab Beta7) and Placebo in the Eucalyptus Phase II Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate Efficacy and Safety in Patients With Refractory Moderate-to-Severely Active Ulcerative Colitis. Gastroenterology. 144(5). S–36. 10 indexed citations

15.

Rutgeerts, Paul, Richard N. Fedorak, Daan W. Hommes, et al.. (2012). A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Gut. 62(8). 1122–1130. 111 indexed citations

16.

Emu, Brinda, Diana Luca, Jane L. Grogan, et al.. (2012). Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial. Arthritis Research & Therapy. 14(1). R6–R6. 26 indexed citations

17.

Rutgeerts, Paul, Richard N. Fedorak, Daniël W. Hommes, et al.. (2011). A Phase I Study of rHuMab Beta7 in Moderate to Severe Ulcerative Colitis (UC). Gastroenterology. 140(5). S–125. 6 indexed citations

18.

Valentini, Piero, Pasquale De Sole, Diana Luca, et al.. (2006). Decreased chemiluminescence in leukocyte adhesion deficiency presenting with recurrent sepsis, amoebiasis and Candida albicans urinary tract infection.. PubMed. 97(5). 437–42. 2 indexed citations

19.

Leri, O, et al.. (1997). Management of diarrhoeic type of irritable bowel syndrome with exclusion diet and disodium cromoglycate. Inflammopharmacology. 5(2). 153–158. 24 indexed citations

20.

Leri, O, et al.. (1996). Type 2 autoimmune hepatitis and hepatitis C viraemia.. PubMed. 18(1). 3–6. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact